ホーム › 慢性リンパ性白血病 › オハイオ › Columbus
Columbus、OHにおける慢性リンパ性白血病の臨床試験
Columbusとその周辺地域（約30マイル以内）の拠点で、慢性リンパ性白血病に関する28件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
被験者募集中第3相
- Ohio State University Comprehensive Cancer Center, Columbus
- Columbus Oncology and Hematology Associates Inc, Columbus
- Riverside Methodist Hospital, Columbus
- 他8件
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- Ohio State University Comprehensive Cancer Center, Columbus
- Mount Carmel East Hospital, Columbus
- The Mark H Zangmeister Center, Columbus
- 他8件
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
被験者募集中第3相
- Study Site 104, Columbus
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
被験者募集中第3相
- Ohio State University Comprehensive Cancer Center, Columbus
Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia
被験者募集中第2相
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
被験者募集中第2相
- The Ohio State University, Columbus
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
被験者募集中第2相
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
被験者募集中第1/2相
- Research Site, Columbus
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
被験者募集中第1相
- The James Cancer Hospital and Solove Research Institute, Columbus
Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
被験者募集中第2相
- Ohio State University Comprehensive Cancer Center, Columbus
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
被験者募集中第3相
- OSU Comprehensive Cancer Center, Columbus
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
被験者募集中第1/2相
- The Ohio State University Wexner Medical Center, Columbus
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
被験者募集中第1相
- The Ohio State University, Columbus
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
被験者募集中第2相
- Ohio State University Comprehensive Cancer Center, Columbus
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
被験者募集中第1相
- Nationwide Children's Hospital, Columbus
- Ohio State University Comprehensive Cancer Center, Columbus
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
被験者募集中第1相
- The Ohio State University, Columbus
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
被験者募集中第4相
- Ohio State University Comprehensive Cancer Center, Columbus
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
被験者募集中第4相
- Ohio State University Comprehensive Cancer Center, Columbus
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
被験者募集中第2相
- Ohio State University Comprehensive Cancer Center, Columbus
Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
被験者募集中第2相
- Ohio State University Comprehensive Cancer Center, Columbus
Study of SGR-1505 in Mature B-Cell Neoplasms
被験者募集中第1相
- The Ohio State University - The James Cancer Hospital, Columbus
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
被験者募集中第2相
- The Ohio State University /ID# 230439, Columbus
Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia
被験者募集中第2相
- Ohio State University Comprehensive Cancer Center, Columbus
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
被験者募集中第2相
- The Ohio State University Comprehensive Cancer Center, Columbus
Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
被験者募集中第2相
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
被験者募集中第1相
- The Ohio State University - The James Cancer Hospital and Solove Research Institute, Columbus
HPC Offered for PRESERVE Expansion
被験者募集中観察研究
- The Ohio State University Medical Center, Columbus
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
被験者募集中第1/2相
- The Ohio State University Comprehensive Cancer Center, Columbus
他の都市における慢性リンパ性白血病の試験
- Boston, MA31件の研究
- Durham, NC27件の研究
- Washington, DC22件の研究
- Seattle, WA20件の研究
- Rochester, MN19件の研究
- New York City, NY18件の研究
- Houston, TX17件の研究
- Baldwin Park, CA16件の研究
- Milwaukee, WI15件の研究
- Cincinnati, OH14件の研究
- Chicago, IL14件の研究
- Nashville, TN13件の研究
Columbusにおける他の研究
- 非小細胞肺癌56件の研究
- 乳がん39件の研究
- 卵巣がん39件の研究
- がん（全種類）38件の研究
- 肺がん37件の研究
- 急性骨髄性白血病35件の研究
- 転移性癌27件の研究
- 子宮内膜がん25件の研究
- 大腸癌24件の研究
- 前立腺がん24件の研究
- 多発性骨髄腫24件の研究
- 悪性黒色腫21件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。